Compare PLSE & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | STOK |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2015 | 2019 |
| Metric | PLSE | STOK |
|---|---|---|
| Price | $24.74 | $31.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $22.00 | ★ $39.20 |
| AVG Volume (30 Days) | 347.1K | ★ 478.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $12.56 | $9.36 |
| 52 Week High | $27.98 | $40.22 |
| Indicator | PLSE | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 46.87 |
| Support Level | $17.58 | $30.34 |
| Resistance Level | $27.14 | $35.11 |
| Average True Range (ATR) | 1.82 | 1.54 |
| MACD | 0.15 | 0.07 |
| Stochastic Oscillator | 67.22 | 52.53 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.